1. Fluorogenic in vitro activity assay for the main protease Mpro from SARS-CoV-2 and its adaptation to the identification of inhibitors
- Author
-
Julien Ihssen, Greta Faccio, Urs Spitz, Chunyan Yao, and Teja Sirec
- Subjects
Science (General) ,In silico ,High-throughput screening ,medicine.medical_treatment ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,In Vitro Techniques ,Antiviral Agents ,General Biochemistry, Genetics and Molecular Biology ,chemistry.chemical_compound ,Viral Proteins ,Q1-390 ,Coumarins ,Drug Discovery ,Health Sciences ,medicine ,Protocol ,Fluorescence Resonance Energy Transfer ,Humans ,Protease Inhibitors ,Clinical Protocol ,Coronavirus 3C Proteases ,Protease ,General Immunology and Microbiology ,PROTEASE M ,Chemistry ,SARS-CoV-2 ,General Neuroscience ,Biotechnology and bioengineering ,COVID-19 ,Coumarin ,High Throughput Screening ,In vitro ,High-Throughput Screening Assays ,COVID-19 Drug Treatment ,Förster resonance energy transfer ,Biochemistry ,Molecular/Chemical Probes - Abstract
This protocol describes an in vitro fluorogenic assay to measure the proteolytic activity and identify inhibitors of Mpro, the main protease produced by SARS-CoV-2. Studies to identify potential inhibitors of Mpro mainly rely on in silico molecular dynamics simulations or on FRET substrates. The protocol is based on an aminomethyl coumarin substrate. High sensitivity, specificity, and an easily detectable fluorescent read-out are the advantages offered by this rapid assay, which allows high throughput screening of new Mpro inhibitors., Graphical Abstract
- Published
- 2021